Labcorp has announced nationwide availability for the Agilent PD-L1 IHC 22C3 pharmDx, a critical companion diagnostic for identifying ovarian cancer patients eligible for Merck’s KEYTRUDA therapy.
Thermo Fisher Scientific has unveiled the Gibco CHOvantage GS, a next-generation biologics development platform designed to accelerate timelines to the clinic while ensuring regulatory compliance and scalability.
IQVIA Holdings Inc. announced it has entered into an agreement to acquire certain discovery services assets from Charles River Laboratories. The acquisition includes five sites specializing in in vitro drug discovery services, supported by over 20 years of scientific data, creating an industry-leading integrated drug discovery platform.
Charles River Laboratories reported 2025 full-year revenue of $4.02 billion, down 0.9% from 2024, with non-GAAP earnings per share of $10.28. The company faced headwinds in its Discovery and Safety Assessment and Manufacturing segments, though Q4 bookings showed substantial improvement, signaling stabilization in the biopharmaceutical market. CEO James C. Foster stated the company is “cautiously optimistic” about 2026, expecting organic revenue growth in the second half of the year. For 2026, management projects non-GAAP EPS of $10.70-$11.20, representing 4-9% growth, driven by cost savings from restructuring initiatives and a lower tax rate. Strategic acquisitions and operational efficiency improvements remain core to the company’s growth strategy.
A landmark study by Ohio State scientists reveals the underlying mechanism of cancer immunotherapy failure: a fatal “proteotoxic shock” or protein quality control collapse (TexPSR) in T-cells. This newly identified stress pathway overwhelms immune cells with misfolded proteins, disabling their tumor-fighting function. Crucially, blocking the TexPSR pathway in preclinical models restored T-cell function and made immunotherapy markedly more effective, offering an entirely new target for cancer treatment development.
Novo Nordisk’s new studies presented at ESC Congress 2025 highlight semaglutide’s powerful cardiovascular benefits for people with diabetes and obesity, showing substantial reductions in heart attack, stroke, and cardiovascular death risks with Wegovy, Ozempic, and Rybelsus.
Eight healthy babies have been born in the UK using a revolutionary “three-person IVF” technique called mitochondrial donation. This groundbreaking procedure, led by scientists at Newcastle University, successfully prevents the transmission of incurable, inherited genetic diseases from mother to child, offering new hope to families worldwide.
The University of California San Francisco Medical Center researchers have discovered four different gene classes that contribute to the explanation of why certain brain regions [Read More…]
Chronic pain is a crippling illness that significantly lowers quality of life and frequently results in a dependence on opioid drugs, which have serious adverse [Read More…]
Researchers at UPMC and Penn State have developed a new mRNA vaccine platform that is more scalable and adaptable, offering rapid protection against viruses like COVID-19 and H5N1.
